Certolizumab and adalimumab are the two most noteworthy biologics behind this recent rise in biologic treatments for Crohn’s patients in remission, but infliximab remains the most prevalent biologic treatment for Crohn’s Disease on the market.
More Articles on Gastroenterology:
Columbus Regional Health Opens $3.8M Endoscopy Center
How Much do Gastroenterologist Make? 27 Statistics
Swallow Solutions Launches Dysphagia Treatment Device
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
